Manchester Science Park’s acquisition of AstraZeneca’s Alderley Park site
Manchester Science Parks (MSP)
today closed a great year for the Bruntwood owned business, with a
strong financial performance, the launch of plans to triple the
size of its core Manchester campus and to acquire Alderley Park,
AstraZaneca's flagship R&D site, in a deal which will catapult
MSP to the forefront of commercial life sciences in the North of
An investment programme which
included the refurbishment of The MedTech Centre, a medical
technology hub incubator which is joint venture between Central
Manchester University Hospitals NHS Foundation Trust, TRUSTECH and
MSP that can hold up to 70 companies, has helped deliver a 91%
occupancy level for MSP and impressive finance results for the year
ending September 2013.
Further growth comes from today exchanging contracts on
AstraZeneca's 400 acre site, Alderley Park, in Cheshire. The
acquisition is funded by MSP, Bruntwood and Cheshire East Council,
with Bruntwood as the majority funder.
MSP plans to build on Alderley Park's heritage of scientific
innovation, retaining the assets and talent at the campus and
repurposing it as a life science business cluster that establishes
the North West as a driver of science sector growth for the UK.
Chris Oglesby, Chairman of MSP and Chief Executive of Bruntwood,
said: "This is a truly unique opportunity to take on one of the
best invested sites in the world, complete with state of the art
facilities and equipment for bioscience companies.
"We are delighted to have been entrusted with securing the
future of Alderley Park as a life science facility of world class
scale and quality. We are committed to developing a sector-led
business cluster of international importance on the site, making it
a flagship location of its kind for the North of England and the
Rowena Burns, Chief Executive, MSP, added: "Our overall strategy
and vision is to bring together the strengths of Alderley Park, as
a bioscience R&D facility of unique scale and quality, with the
existing MSP clusters and links to the knowledge base to create an
internationally compelling commercial science offer and driver of
future economic growth.
"We're making huge strides in securing MSP's place as the driver
of innovation in the city region and as an organisation that helps
to bring great ideas to the world. Our work in growing the Corridor
campus and securing the legacy of Alderley Park will significantly
raise our presence and profile in the region and beyond."
Mike Deegan, the CMFT CEO said "The recent acquisition of Astra
Zeneca's Alderley development by Manchester Science Park (MSP) is
fantastic news for life science industry and healthcare innovation,
not only in Manchester but for the UK. With more life sciences
companies choosing to locate to Alderley Park, it will give CMFT
and MSP opportunity to work in partnership with these companies to
develop the new diagnostics and therapeutics that we need to drive
innovation to improve patient care.
"CMFT is already working in partnership with MSP and Bruntwood
through Citylabs, a £24m biomedical centre of excellence, located
on the CMFT campus, which is due to open June 2014 and is currently